Researchers at Johns Hopkins Medicine say they have created a laboratory-grown three-dimensional "organoid" model that is derived from human tissue and designed to advance understanding about how early stages of cancer develop ...
Dec 1, 2022
0
39
Patients with esophageal cancer who survive 5 years after undergoing surgery might breathe a sigh of relief and become complacent about continued monitoring. In fact, there is little published information on the outcome of ...
Apr 29, 2015
0
6
(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.
Dec 14, 2014
0
0
(HealthDay)—Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach or of the area where the esophagus joins the stomach (the gastroesophageal junction).
Apr 22, 2014
0
0
During the past 30 years, the number of patients with cancers that originate near the junction of the esophagus and stomach has increased approximately 600 percent in the United States. The first extensive probe of the DNA ...
Mar 24, 2013
0
0
(HealthDay)—Patients with gastric and gastroesophageal junction (GEJ) cancer who survive for longer than three years after diagnosis seem to have distinct demographic and pathologic characteristics, compared with those ...
Sep 7, 2012
0
0
